Cardiff Oncology, Inc.
CRDFHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeCardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Valued at $70.6M, CRDF is a micro-cap name in its sector. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Market Cap
$70.6M
Beta
1.42
P/E (TTM)
—
P/E (Fwd)
-1.70
EPS (TTM)
$-0.58
EPS (Fwd)
$-0.54
ROE
-94.1%
ROA
-46.7%
Cash
$34.5M
Total Debt
$457,000
Free CF
-$24.3M
52W Change
-59.2%
Annual Financials
Cash vs Debt
Where CRDF stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CRDF finished 33.08% below its 150-day moving average ($1.33) and 41.83% below its 200-day moving average ($1.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRDF overbought or oversold?
At the October 20, 2026 close, CRDF's RSI(14) was 20.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $34.5M in cash and $457K in debt, CRDF maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$24.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -94.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $386K (2022) to $593K (2025), reflecting a 54% increase over the period.
With cash comfortably exceeding debt, CRDF has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CRDF's risk profile alongside its fundamentals and technical indicators provides a more complete picture.